ArticleJournal of comparative effectiveness research2025
Cost-effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting.
Rupesh Subash et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.